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Abstract
Background
Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treat-
ment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effec-
tive and well-tolerated strategy. However, the effectiveness of this approach has not been
established.
Methods
We performed a retrospective study evaluating the rates of treatment failure, virological fail-
ure (VF), and variables associated, in all subjects initiating this switch combination in our
clinic since 2001. Analyses were performed by a modified intention to treat, where switch
due to toxicity equalled failure. The main endpoint was plasma HIV-RNA < 50 copies/mL.
Results
341 patients were treated for a median of 176 (57; 308) weeks. At week 48, 306 (89.7%)
subjects had HIV-1 RNA <50 copies/mL, 10 (2.9%) experienced VF, and 25 (7.4%) discon-
tinued the treatment due to toxicity. During the whole follow-up 23 (6.7%) individuals (17 on
lamivudine, 6 on emtricitabine; p = 0.034) developed VF and treatment modification due to
toxicity occurred in 36 (10.7%). Factors independently associated with VF in a multivariate
analysis were: intravenous drug use (HR 1.51; 95%CI 1.12, 2.04), time with undetectable
viral load before the switch (HR 0.98; 0.97, 0.99), number of prior NRTIs (HR 1.49; 1.15,
1.93) or NNRTIs (HR 3.22; 1.64, 6.25), and previous NVP (HR 1.54; 1.10, 2.17) or efavirenz
(HR 5.76; 1.11, 29.87) unscheduled interruptions. VF was associated with emergence of
usual nevirapine mutations (Y181C/I/D, K103N and V106A/I), M184V (n = 16; 12 with lami-
vudine vs. 4 with emtricitabine, p = 0.04), and K65R (n = 7).
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Conclusions
The rates of treatment failure at 48 weeks, or long-term toxicity or VF with this switch regi-
men are low and no unexpected mutations or patterns of mutations were selected in sub-
jects with treatment failure.
Introduction
Many subjects on suppressive antiretroviral therapy (ART) may be considered candidates for
long-term regimen simplification towards easier to administer, more tolerable, or more cost-
effective regimens [1–3]. Treatment guidelines consider that boosted protease inhibitors (PI)
or efavirenz may be switched for toxicity, simplification, prevention or improvement of meta-
bolic abnormalities or adherence facilitation to unboosted atazanavir, non-nucleoside reverse
transcriptase inhibitors (NNRTIs; NVP, efavirenz, rilpivirine), or integrase inhibitors (raltegra-
vir or elvitegravir/cobicistat) [1–7].
Nevirapine (NVP) displayed similar rates of efficacy at 12 and 36 months against efavirenz
in simplification [8–13], and achieved the lowest rates of virological failure and higher lipid
benefits in the extended three-year follow-up in a randomized study [12;14;15]. However,
some observational cohorts found higher rates of virological failure with nevirapine versus efa-
virenz [16–18]. Baseline uncontrolled biasing factors, mainly differences in calendar year of
prescription, could have an impact on the results of these cohorts. In addition, it is one of the
antiretroviral drugs that achieve higher reductions of residual plasma viremia to below 1 copy/
mL and a better lipid profile [15;19–21]. Pre-treated individuals with high CD4 cell counts do
not have the increased risk for treatment-limiting toxicity seen in naives, provided there is no
detectable viremia at initiation of NVP [22]. NVP has a well-known initial potential toxicity
profile, and has not been associated to any specific long-term toxicity.
Among the newest drugs, only elvitegravir/cobicistat has been evaluated in randomized
studies as a switch strategy for subjects receiving NVP [7]. It demonstrated non-inferior effi-
cacy in the substitution of efavirenz or nevirapine, albeit the sole benefit (lipid profile) in the
study was seen only in the efavirenz subgroup. Therefore, maintenance of generic NVP in
long-term therapy might offer a powerful approach to cost-savings in well-resourced countries,
and be a common strategy in countries with limited treatment options [23]. However, some
patients and physicians may believe that a new brand-name drug is superior or more appealing,
and could be reluctant to maintain an effective antiretroviral regimen based on a generic drug.
The combination of once-daily NVP plus TDF/FTC (or 3TC) has been extensively used as a
long-term simplification regimen in some European countries, however information about the
efficacy and long-term toxicity of this regimen is still scant [24;25]. Furthermore, 3TC has been
associated with lower virological responses compared to FTC in some reports in naives, includ-
ing one with NVP and TDF, but data are not available in simplification [26].
Therefore, accurate data on the long-term efficacy and toxicity of NVP plus TDF/FTC (or
3TC) as a switch regimen—with particular focus on the rates of VF or any particular pattern of
unexpected mutations—are needed.
Methods
Study design and study subjects
We performed a retrospective cohort study of HIV-infected patients attending a tertiary Uni-
versity Hospital in Barcelona, Spain since 2001, when all drugs became available. All subjects
aged18 years with documented HIV-1 infection were included if they started treatment with
Risk of Failure to NVP plus TDF plus FTC/3TC
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NVP plus TDF plus FTC (or 3TC) as a switch from any previous regimen, with an undetectable
plasma viral load (pVL), and had at least one subsequent follow-up visit. The inclusion criteria
allowed incorporating subjects with early withdrawal of the regimen due to toxicity. Subjects
were followed until they stopped the regimen for any reason. The study was approved by the
Hospital Research Ethics Committee and conducted in accordance with the Declaration of
Helsinki and National standards.
Historical follow-up data were extracted from medical records through a systematic data-
base search. No restriction criteria were included in the search. All causes of treatment discon-
tinuation were registered. VF was defined as two consecutive pVL>50 copies/ml.
Baseline characteristics were gathered, including age, gender, risk factor for HIV acquisition,
time of HIV infection, number of prior antiretroviral drugs and antiretroviral regimens, prior
NRTI mono or dual therapy, time with HIV-1 RNA suppression before the switch, hep B or C
co-infection, and reason to initiate the study regimen. CD4+ cell counts and pVL were collected
every 12–24 weeks thereafter, until the last sample available.
The complete previous treatment history was searched, and all previous NNRTI interrup-
tions were recorded, as well as all prior treatment failures.
Genotypic resistance tests prior to the initiation of the regimen and the available resistance
studies in those patients who failed were collected.
Statistical analysis
Patients’ characteristics were described using medians (IQR) for continuous, non-normal vari-
ables and percentages for categorical variables.
The primary endpoint was the proportion of subjects with pVL<50 copies/mL at 48 weeks.
We based our efficacy and safety analyses on a modified intent-to-treat (mITT, S = F) exposed
or safety populations, which consisted of all patients initiating the regimen with any treatment
discontinuation due to toxicity or voluntary treatment discontinuation considered as treatment
failure. Subjects substituting 3TC with FTC during the study were not considered failures.
Patients lost to follow-up or withdrawing the regimen due to reasons unrelated to toxicity (i.e.
recruited into a clinical trial) or efficacy were censored at that time in the analysis, provided
they had a pVL<50 c/mL and no toxicity at that visit, considering that this was a retrospective
study and subjects were not tied up to an allocated treatment.
VF and factors associated with it were also pre-planned analyses. A secondary analysis
assessed the percentage of patients remaining on the same regimen with a pVL< 50 copies/mL
at the end of follow-up.
A relevant list of covariates was included in a multivariate Cox proportional model to deter-
mine factors independently associated with VF. The model was adjusted for age, intravenous
drug use, hepatitis C co-infection, number of prior NNRTIs received, prior NNRTI treatment
interruptions, presence of 3TC (versus FTC) in the regimen, inclusion of NVP in the last regi-
men, and duration of HIV-1 infection.
All variables with a significant association (p<0.05) in the univariate analysis were intro-
duced into the multivariate model. The multivariate analysis was run in the overall cohort and
also excluding subjects already on NVP at the time of the switch. The duration of treatment
and time to VF were estimated using the Kaplan-Meier method. All statistical analyses were
performed using SPSS software for Windows (version 15.0; SPSS Inc, Chicago, IL, USA).
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Results
Baseline characteristics
We identified 367 patients having started a combination including NVP plus TDF plus FTC
(or 3TC). Of them, 26 were treatment naïve when they initiated this combination, and were
excluded. Cohort demographics of the remaining 341 are shown in Table 1. Most study sub-
jects were male (72%), with a mean age of 42 years. The mean time with undetectable pVL at
regimen initiation was 48 months, and had been exposed to a median number of 6 drugs. Prior
VFs before initiating NVP were documented in 24% of them.
Reasons for initiation of the regimen
The main reasons for initiating the switch regimen were prior drug toxicity (169, 49.6%), treat-
ment simplification (149, 43.7%), and pregnancy desire (5, 1.5%).
Patient disposition at 48 weeks
Overall, 295/341 (86.5%) patients had a pVL<50 copies/mL at 48 weeks (mITT, S = F), and 10
(2.9%) experienced confirmed VF at 48 weeks. Drug toxicity led to treatment discontinuation
in 22 (6.6%) subjects, and 14 (4.0%) experienced a voluntary treatment discontinuation.
Toxicity was specifically assessed in all NVP-naïve subjects at the initiation of the study regi-
men (168 out of 341). Of them, NVP was discontinued in 20 (11.9%), mainly due to early
development (most of them at first trimester) of rash or laboratory liver abnormalities. Only 3
(2%) subjects developed grade 4 transaminase increases, none a severe clinical liver event, and
none grade 4 rash.
In an on-treatment analysis, 96.2% of subjects receiving NVP at 48 weeks had a pVL<50
copies/mL.
Patient disposition at the last follow-up visit
Patients stayed on the regimen for a median of 176 (57; 308) weeks and 215 (63.5%) patients
discontinued the study regimen at any time during the follow-up. The reasons for treatment
discontinuation at the last available control were: lost to follow-up (43, 12.6%), voluntary treat-
ment interruption (37, 10.9%), recruitment for a randomized clinical trial (37, 10.9%), toxicity
(34, 10.1%), confirmed VF (23, 6.7%; 17 on 3TC and 6 on FTC, p = 0.034), subsequent treat-
ment simplification (18, 5.3%). Among individuals with immune discordance despite a sup-
pressed viremia, 21 (6.1%) received proactive treatment changes (most of the latter empirically
switched NVP to a PI/r, a common practice during some years). Therefore, only 57 (16.8%)
subjects discontinued the treatment due to toxicity or lack of efficacy at 4 years.
Hence 156 (45.8%) patients discontinued the study regimen or follow-up in real clinical
practice due to reasons unrelated to treatment efficacy. Of the overall cohort, 126 (37.3%) were
still on the same regimen and with an HIV-RNA<50 copies/mL in their last control available
(median 4 years). The median time to VF and treatment discontinuation are depicted in Fig 1.
Factors associated with VF
In a multivariate analysis adjusted for variables described in Table 2, factors independently
associated with VF were: intravenous drug use (HR 1.51; 95%CI 1.12, 2.04), longer time with
undetectable pVL before regimen initiation (HR 0,98; 0.97, 0.99), number of prior NRTIs
received (HR 1.49; 1.15, 1.93), number of prior NNRTIs received (HR 3.2; 1.6, 6.3), prior NVP
interruptions (HR 1.54; 1.10, 2.17), prior efavirenz interruptions (HR 5.76; 1.11, 29.87), and
Risk of Failure to NVP plus TDF plus FTC/3TC
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Table 1. Patient characteristics at the initiation of NVP plus TDF plus FTC (or 3TC) as a switch strategy
(n = 341).
Age (yrs, mean [SD]) 42.2 (8.7)
Gender (male, %) 246 (72)
Risk category for HIV acquisition (n, %)
MSM 125 (37.3)
Intravenous Drug Users 92 (27.5)
Heterosexual 92 (27.5)
Other 32 (9.4)
Hepatitis B or C Co-infection (n, %)
Hep C 98 (29.8)
Hep B 25 (7.7)
Pregnancy 7 (7.4)
Nadir CD4 cell count (cells, mean [SD]) 239 (148)
Baseline CD4 cell count (cells, median [IQR]) 492 (331,7)
Time of HIV-1 infection (months, mean [SD]) 128 (69)
Time with undetectable viral load at regimen initiation 48 (33)
(months, mean [SD])
Prior Antiretroviral exposure (n of drugs, median [IQR]) 6 (4,8)
Number of prior NRTI 4 (2,5)
Number of prior NNRTI 1 (1,1)
Number of prior PI 1 (1,2)
Prior NRTI mono or dual therapy (n, %) 146 (43)
Both NRTI mono and dual NRTI prior therapy 60 (18)
Prior virologic failures documented (n, %) 79 (24)
Prior NNRTI documented treatment interruption (n, %) 99 (29.2)
NNRTI interruption only once 1 (23)
More than 1 NNRTI interruption 44 (13)
Drug previously interrupted:
Nevirapine 60 (18)
Efavirenz 18 (5)
Viral load at baseline < 50 copies/mL (n, %) * 264 (78.3)
Lamivudine present in the last regimen 193 (57)
Emtricitabine present in the last regimen 66 (19)
Tenofovir present in the last regimen 126 (37)
Nevirapine present in the last regimen 173 (51)
Drug substituted by NVP
Efavirenz 56 (33)
Protease inhibitor (indinavir, nelﬁnavir, saquinavir) 40 (24)
Boosted protease inhibitor (lopinavir, atazanavir, darunavir) 60 (36)
Other (raltegravir, etravirine) 12 (7)
Received 3TC + NVP + TDF 159 (47)
Received FTC + NVP + TDF 182 (53)
Data are median (IQR) or n (%).
* Some individuals in the early calendar years had an undetectable viral load at baseline, but with tests
using at that moment a threshold of 80 or 200 copies/mL.
MSM: Men having sex with men; NRTI: Nucleos(t)ide reverse transcriptase inhibitor; NNRTI: non-
nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor.
doi:10.1371/journal.pone.0128131.t001
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NVP being present in the last regimen prior to current simplification (HR 0.57; 0.43, 0.76).
Other factors significantly associated with VF in univariate analysis are shown in Table 2.
Resistance selection at failure
Population genotypes at failure were available in all 23 subjects (6.7%) experiencing confirmed
VF (Table 3). None of them had previous resistance tests available. Wild-type HIV-1 was seen
in 5 (22%) of them. Sixteen out of 23 (70%) had NNRTI mutations (Y181C/I/D: 10; K103N: 6;
V106A/I: 3; Y188C/L: 2; K101Q/E: 2; M230L: 1; P225H: 1; A98G: 1; V108I: 1; F227L: 1; K238T:
1), and 10 had>1 NNRTI mutation.
M184V was selected in 16 (70%) subjects: 12 treated with 3TC and 4 with FTC (p = 0.04).
Seven patients had K65R (6 associated to M184V, none with thymidine-analogue mutations
[TAMs]), 5 of them treated with 3TC and 2 with FTC. Six patients selected A62V, with K65R
selected in 4 of them, and none with Q151M or T69 insertions. Five patients harboured TAMs.
Three subjects harboured major protease mutations (V32I, M46I, I47V, L90M), selected in
prior failures.
Fig 1. Time to virological failure and treatment failure through the long term follow-up. Virological failure was defined as two consecutive
measurements of pVL >50 copies/mL. Treatment failure included subjects with virological failure, treatment discontinuations due to drug toxicity, and death.
doi:10.1371/journal.pone.0128131.g001
Risk of Failure to NVP plus TDF plus FTC/3TC
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Discussion
The 48-week (2.9%) and long-term (6.7% at 4 years) rates of VF of a switch regimen composed
of NVP plus TDF plus FTC (or 3TC) in real clinical practice are low, and similar to those of
other common switch strategies seen in similar cohorts and recommended in international
guidelines [1;2;27;28]. These strategies include unboosted atazanavir, rilpivirine, raltegravir or
elvitegravir/cobicistat, and the corresponding rates of VF in their pivotal clinical trials were
1–8% [7;29;30]. However, data from prospective clinical trials are not comparable to those of
cohorts including patients seen in everyday circumstances, and the rates of VF reported in
cohorts have been higher and similar to our series [5;7;28–32]. Actually, raltegravir showed
higher rates of VF in a randomized switch clinical trial (9.1% at 24 weeks), early terminated by
a DSMB because of lower than expected virological efficacy [33;34].
Whilst VF was infrequent, drug resistance mutations against NNRTIs and NRTIs were fre-
quently isolated in patients with VF, in agreement with what has been seen in pivotal trials
with NVP in naives, and also with other drugs with a similarly low genetic barrier to resistance
(efavirenz, rilpivirine, raltegravir and elvitegravir/cobicistat) in initial therapy [31;33–42]. On
Table 2. Factors associated with virologic failure to a switch regimen composed of NVP plus TDF plus FTC (or 3TC) (n = 341).
Univariate Multivariate
Variable HR (95% CI) p value HR (95% CI) p value
Age 0.99 (0.96, 1.03) 0.76
Gender 1.41 (0.72, 2.78) 0.31
Intravenous Drug Users 1.98 (1.09, 3.58) 0.02 1.51 (1.12, 2.04) 0.01
Hepatitis B or C Co-infection
Hep C 1.58 (0.87, 2.87) 0.13
Hep B 0.90 (0.32, 2.52) 0.85
Nadir CD4 cell count 0.98 (0.79, 1.22) 0.86
Baseline CD4 cell count 0.80 (0.69, 0.92) 0.00
Time of HIV-1 infection 1.00 (1.00, 1.00) 0.92
Longer time with undetectable VL 0.98 (0.97, 1.00) 0.01 0.98 (0.97, 0.99) 0.01
Prior Antiretroviral exposure 1.01 (0.89, 1.13) 0.93
number of prior NRTI 1.18 (0.97, 1.43) 0.10 1.49 (1.15, 1.93) 0.00
number of prior NNRTI 2.38 (1.49, 3.85) 0.00 3.22 (1.64, 6.25) 0.00
number of prior PI 1.03 (0.81, 1.31) 0.82
Prior NRTI mono and dual therapy 1.14 (0.65, 2.01) 0.65
Prior VF documented 1.76 (0.96, 3.25) 0.07
Prior NNRTI treatment interruption 2.13 (1.20, 3.78) 0.01
Nevirapine interruptions 1.72 (0.86, 3.45) 0.13 1.54 (1.10, 2.17) 0.01
Efavirenz interruptions 3.11 (1.23, 7.90) 0.02 5.76 (1.11, 29.87) 0.04
VL at baseline <50 c/mL * 0.22 (0.12, 0.39) 0.00
3TC present in the last regimen 0.72 (0.40, 1.30) 0.27
FTC present in the last regimen 0.30 (0.04, 2.18) 0.23
TDF present in the last regimen 1.01 (0.53, 1.95) 0.97
NVP present in the last regimen 0.32 (0.18, 0.57) 0.00 0.57 (0.43, 0.76) 0.00
3TC (vs FTC) in the regimen 2.48 (1.38, 4.46) 0.00
* Some individuals in early calendar years had an undetectable viral load at baseline, but with tests using a threshold of 80 or 200 copies/mL.
VL: viral load; VF: virologic failures; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside analogue reverse transcriptase inhibitor; PI:
protease inhibitor.
doi:10.1371/journal.pone.0128131.t002
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the other hand, unboosted atazanavir maintains a high genetic barrier to resistance in switch
despite the absence of pharmacokinetic boosting, and no major protease mutations isolated in
failures in randomised clinical trials even in the long term, albeit they have indeed been
reported in some cohorts in real clinical practice [28;29].
Reassuringly, the frequency and type of mutations seen in our series was concordant with
what has been previously seen in other NVP studies, with a potential impact of some of them
against the activity of etravirine in subsequent treatments [43]. The most common emergent
NNRTI mutations were Y181C/I/D, K103N and V106A/I [44].
The rate of K65R selection was low was, but appeared in approximately one of every three
failures, usually with M184V, and more frequently in those treated with 3TC (vs FTC) [35;36].
We observed a significantly higher rate of VF in individuals treated with 3TC instead of
FTC, with a significantly higher rate of selection of M184V as well. Nevertheless, these data
must be interpreted with caution, as calendar years when subjects received 3TC or FTC were
Table 3. Mutations shown at failure in the reverse transcriptase and protease, and NRTI included in
the regimen together with NVP and TDF (3TC vs FTC).
3TC/
FTC
Reverse transcriptase Protease
FTC A62V,K65R,Y181C,M184V None
FTC A62V, K65R, V75I, K103N, Y181C, M184V,
M230L,
L63P
3TC A62V,L74V,K103N,V106A,M184V,T215S,
P225H
L63P
3TC A62V, K65R, K101Q, Y181C K20M, M36I, M46I, Q58E, L63P, L90M, I93L
3TC V118I, M184V, Y188C L63P
FTC M41L, E44D, D67N, K70R, M184V, T215Y,
K219Q
L63P
3TC Y181I, M184V G16E
3TC M41L,A62V,T69N,K70R,K103N,V108I,M184V,
T215F,K219E
R41K, L63P, A71V, V77I, L90M, I93L
3TC D67N, K103N, Y181C, M184V, K219E I62V, I64V
3TC None L63P
3TC A62V, K65R, A98G, Y181C, M184V L63P
3TC K65R, M184V, Y188L I15V,V77I, I93L
FTC None (wild-type) V77I
FTC L74V/L, Q102K/R, K103K/N, D177E/G, Y181Y/
D, M184V, G190G/A
K20R, M36I, L63P
3TC K65R, V108I, Y181C, M184V 13V, K20T, V32I, E35D, M36I, K43T, M46I,
I47V, F53L, L63P, I66F, A71V, G73S, V77I,
L90M,
3TC M41L, E44D, D67N, T69D, V118I, Y181C,
M184V, G190A, L210W, T215Y, V106V/I,
F227F/I
L33V
3TC None M36I,L63P,V77I
3TC K103N/S,Y181C,M184V L33V, R41K, I64V, I13V/I, L63P
FTC K101E, G190A, K238T L10V, I13V, L63P
3TC None I13V, M36I, L63P
3TC M41L, M184V, L210W, T215Y V118I
3TC None I13V, L63P, V77I
3TC K65R, V106A, M184V None
doi:10.1371/journal.pone.0128131.t003
Risk of Failure to NVP plus TDF plus FTC/3TC
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different—as well as the number of pills in the regimen—and unmeasured confounders could
exist. However, this is concordant with a double risk of VF (adjusted OR 2.2; 95%CI 1.1, 4.6)
for 3TC vs FTC found in treatment-naives [26;45]. Some previous reports have suggested
potential differing resistance profiles for FTC and 3TC when administered in combination
with TDF [46;47]. Moreover, previous reports have shown differing resistance profiles for FTC
and 3TC when administered in combination with TDF [46;47]. Therefore, our findings suggest
caution against substituting FTC for 3TC, at least in NVP- and TDF-based regimens, while
other series review their data [1]. A shorter intracellular t1/2 of activated triphosphate 3TC
compared to FTC (15 h versus>39 h), a 4- to 10-fold lower antiviral potency of FTC in a
range of cell line in vitro passages, and the ability of FTC to inhibit cellular efflux proteins such
as the multidrug resistance–associated proteins could account for a lower forgiveness of 3TC,
at least when combined with NVP [23;47–49]. This is due to the ability of FTC to inhibit the
activity of the cellular efflux proteins, such as the multidrug resistance–associated proteins,
that extrude the drugs out of the CD4+ cells [47].
No subjects selected NRTI resistance mutations without NNRTI ones, thus confirming that
NNRTI resistance is selected first, in agreement with previous reports [50;51].
In an adjusted multivariate analysis, we found an independent association of VF with intra-
venous drug use, time with undetectable VL, number of prior NRTIs or NNRTIs received, and
prior NVP or efavirenz interruptions. Actually, intravenous drug users and higher antiretrovi-
ral drug exposure are variables universally associated to increased rates of VF to any switch reg-
imen [10;34;52]. The long half-life of NNRTIs, as compared with that of some NRTIs, may
allow a long terminal tail in plasma pharmacokinetics with suboptimal late NNRTI functional
monotherapy in unplanned treatment interruptions. In addition, repeated drug holidays (>48
h of drug cessation) have been previously associated with VF to NVP and efavirenz [52]. These
findings have clinical translation indeed. Some studies using standard and ultrasensitive tech-
niques have been able to detect NNRTI-associated mutations in up to 14–16% of individuals
who discontinued a NNRTI-based regimen with a pVL<50 copies/mL, particularly with a
simultaneous interruption (instead of a staggered interruption) of all drugs in the regimen
[53;54]. Moreover, these interruptions led to a 14-fold increased risk of detecting genotypically
resistant HIV-1-RNA in female genital tract secretions, therefore potentially increasing the risk
of HIV transmission [55].
Therefore, reinitiation of NVP plus TDF plus FTC (or 3TC) should be discouraged in sub-
jects experiencing unplanned treatment interruptions, even with an undetectable pVL at the
time of treatment withdrawal.
The main reasons for initiating the regimen in our series were prior toxicity and treatment
simplification, which still remain as the main reasons currently.
The rates of treatment discontinuation due to adverse events in our cohort (6.6% at 48
weeks, 10.6% overall at 4 years, and 11.9% in those initiating new NVP) are concordant
with rates seen in other NVP or efavirenz studies [10;12;35;36], but are higher than those
observed with some other switch strategies and constitute the main limitation of this regimen
[29;30;33;34]. This is a drug-related effect of NVP, and suspicion of hypersensitivity reactions
or increases in liver transaminases were the most frequent reasons for stopping the regimen,
mainly during the first 12 weeks. These early toxicity-associated withdrawals prevented the
demonstration of non-inferiority versus efavirenz in initial treatment in the 2NN study as well
as in a recent systematic review [56;57]. Grade 4 adverse events were seen in only 2% of the
patients and no severe clinical events were reported among the 341 subjects. Not unexpectedly,
those receiving NVP in their baseline regimen before the switch were indeed less prone to tox-
icity. The greater risk of symptomatic hepatic or skin events, including serious and potentially
life-threatening events, although the latter not observed in our series, may remain an intrinsic
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restriction to new NVP initiation in the future, as compared to the lower intrinsic toxicity of
newest drugs.
However, the most frequent reasons for withdrawing the regimen in real clinical practice
were not related to toxicity or lack of efficacy, but proactive treatment changes, recruitment for
clinical trials, or patients being lost to follow-up, with subjects having suppressed viremia at
that time point.
Generic substitution is one mechanism of curtailing prescription drug expenditures. Cur-
rently available as a generic and with reference pricing, a cost/efficacy assessment done by the
Spanish GESIDA Society has shown that NVP plus TDF/FTC (or 3TC) constitutes a cost-effec-
tive treatment in Europe despite the availability of many new regimens [58]. It is administered
once-daily as a two-pill regimen, and is commonly used in developing countries as well as
developed countries with economic constraints [58].
These findings inform regimen management in clinical practice, and would support the
long-term maintenance of this strategy in subjects without initial toxicity. Actually, newer anti-
retroviral drugs have not demonstrated advantages in switch studies in subjects treated with
NVP plus TDF/FTC [7].
Our study is subject to the limitation of its retrospective design, which could lead to bias
with unmeasured confounding factors such as treatment adherence or channelling prescription
by physicians. We specifically made every effort to capture all subjects receiving the first dose
of the regimen, to avoid underestimation of toxicity. The study included subjects who changed
the whole regimen and subjects who were already receiving NVP and only changed the NRTI
backbone. However, both subgroups have been analysed separately in a sensitivity analysis to
pinpoint the toxicity of NVP. Nonetheless, the study reports the largest cohort of patients
treated with this switch regimen so far, and the results are consistent and robust through
adjusted and sensitivity analyses. Important information gleaned from the study includes
higher risk of failure with such a switch in a setting for subjects who had previously been
exposed to NNRTI and had a history of treatment interruption.
In conclusion, a simplification regimen with NVP plus TDF and FTC (or 3TC) in pre-
treated subjects maintained virologic suppression with a low risk of short and long-term treat-
ment or VF in subjects without prior NNRTI treatment interruptions, and a low rate of long-
term adverse events. The rates of VF are similar to other switch strategies, and no unexpected
mutations or patterns of mutations have been selected at failure. These findings do not suggest
increased early or late VF rates with this regimen when used as a simplification strategy. How-
ever, the rates of discontinuation due to early toxicity were higher. While potentially severe ini-
tial toxicity might limit its new initiation in the future, these data support caution against a
systematic proactive switch of those subjects successfully treated with this regimen towards
newest drugs until clinical advantages to patients are demonstrated in randomised clinical
trials.
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